Search - tctmd.com

Displaying 141 - 160 of 218

Sort: Relevancy | Date

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Dean J. Kereiakes

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB China (TCT Late-Breaking Clinical Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Run-Lin Gao

October 14, 2015

Presentation TCT 2015

New Randomized Trial Data (1-Year Outcomes): ABSORB Japan (ESC Late-Breaking Trial Results and Beyond)

Presenter: Stephen G. Ellis, Patrick W. Serruys, Takeshi Kimura

October 14, 2015

Presentation TCT 2015

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

Presenter: Stephen G. Ellis, Patrick W. Serruys, Davide Capodanno

October 14, 2015

Presentation TCT 2015

Featured Lecture: First Report of the 5-Year Cohort B Multimodality Imaging Results (And My Clinical Predictions Based on These Findings)

Presenter: Stephen G. Ellis, Patrick W. Serruys

October 14, 2015

Presentation TCT 2015

TCT 16: Do Overlapping Scaffolds Have an Impact on Clinical Outcome? Analysis of the ABSORB-EXTEND Single-Arm Study

Presenter: Stephen G. Ellis, Lorenz Raber, Pieter C. Smits

October 13, 2015

Presentation TCT 2015

TCT 15: Multislice Computed Tomography Assessment of Absorb Bioresorbable Vascular Scaffold in Comparison With Metallic Drug-Eluting Stents Data From the ABSORB Japan Trial

Presenter: Stephen G. Ellis, Lorenz Raber, Kengo Tanabe

October 13, 2015

Presentation TCT 2015

TCT 14: ABSORB FIRST One-Year Clinical Outcomes From a Prospective, Multicenter, Global, Real-world Registry

Presenter: Stephen G. Ellis, Lorenz Raber, Ashok Seth

October 13, 2015

Presentation TCT 2015

TCT 13: Clinical Outcomes After Implantation of Absorb BVS in Small Vessels Results From the Italian RAI Multicenter Registry

Presenter: Stephen G. Ellis, Lorenz Raber, Giulia Masiero

October 13, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

Presenter: Ioanna Kosmidou, Bernard R. Chevalier

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Ioanna Kosmidou, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Run-Lin Gao, Gregg W. Stone, Ron Waksman, Run-Lin Gao

October 12, 2015

Presentation TCT 2015

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Gregg W. Stone, Ron Waksman, Dean J. Kereiakes

October 12, 2015

Presentation TCT 2015

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: Bernard Chevalier

October 12, 2015

Presentation TCT 2015

I Want to Treat Vulnerable Plaques: Not Today but Tomorrow (From PROSPECT to PROSPECT ABSORB)

Presenter: Gary S. Mintz, Seung-Jung Park, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Rationale for and Design of HORIZONS-ABSORB

Presenter: Dariusz Dudek, Robert J. de Winter, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

BRS Results to Date: Imaging, Randomized Trials, and Anticipation of ABSORB III

Presenter: Thomas H. Maloney, David G. Rizik

October 11, 2015

Presentation TCT 2015

France Presents: French Absorb Registry Indications and In-Hospital Results

Presenter: George D. Dangas, Eric Van Belle, René Koning

October 11, 2015

Presentation ESC 2015

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Presenter: Takeshi Kimura

September 01, 2015

Advertisement

New Randomized Trial Data (1-Year Outcomes): ABSORB III (TCT Late-Breaking Clinical Trial Results and Beyond)

New Randomized Trial Data (1-Year Outcomes): ABSORB China (TCT Late-Breaking Clinical Trial Results and Beyond)

New Randomized Trial Data (1-Year Outcomes): ABSORB Japan (ESC Late-Breaking Trial Results and Beyond)

Comparative Outcomes of Absorb BVS in the Real-world: Insights From GHOST-EU and XIENCE V USA

Featured Lecture: First Report of the 5-Year Cohort B Multimodality Imaging Results (And My Clinical Predictions Based on These Findings)

TCT 16: Do Overlapping Scaffolds Have an Impact on Clinical Outcome? Analysis of the ABSORB-EXTEND Single-Arm Study

TCT 15: Multislice Computed Tomography Assessment of Absorb Bioresorbable Vascular Scaffold in Comparison With Metallic Drug-Eluting Stents Data From the ABSORB Japan Trial

TCT 14: ABSORB FIRST One-Year Clinical Outcomes From a Prospective, Multicenter, Global, Real-world Registry

TCT 13: Clinical Outcomes After Implantation of Absorb BVS in Small Vessels Results From the Italian RAI Multicenter Registry

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease - Two-Year Outcomes

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Vs. an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

I Want to Treat Vulnerable Plaques: Not Today but Tomorrow (From PROSPECT to PROSPECT ABSORB)

Rationale for and Design of HORIZONS-ABSORB

BRS Results to Date: Imaging, Randomized Trials, and Anticipation of ABSORB III

France Presents: French Absorb Registry Indications and In-Hospital Results

12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs_ metallic DES in de novo native coronary artery lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content